Bone Biologics Corporation carries no debt; cash flow comfortably covers obligations.

Bone Biologics Corporation's free cash flow has increased -34.76% from $-4.12M last year to $-2.69M, signaling increasing performance

Bone Biologics Corporation's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Bone Biologics Corporation has insufficient data to evaluate this check.

Bone Biologics Corporation has negative EBITDA, making leverage ratio unreliable

Bone Biologics Corporation earns at least as much interest as it pays. Interest obligations are fully covered.

Bone Biologics Corporation has insufficient data to evaluate this check.

Bone Biologics Corporation's short-term assets of $5.80M exceed its short-term liabilities of $418.59K

Bone Biologics Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Bone Biologics Corporation's return on equity of -50.45%, is lower than 15.00%, indicating bad performance

Bone Biologics Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Bone Biologics Corporation had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Bone Biologics Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

Bone Biologics Corporation has negative free cash flow, indicating cash burn

Bone Biologics Corporation's yearly earnings has increased -24.39% since last year from $-4.11M to $-3.11M, signaling increasing performance

Bone Biologics Corporation's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -64.27% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Bone Biologics Corporation has insufficient revenue history to calculate 3-year revenue CAGR.

Bone Biologics Corporation had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Bone Biologics Corporation had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Bone Biologics Corporation has insufficient data to evaluate this check.

Bone Biologics Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Bone Biologics Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Bone Biologics Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Bone Biologics Corporation has insufficient data to evaluate this check.

Bone Biologics Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Bone Biologics Corporation has a price-to-book ratio of 0.48x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Bone Biologics Corporation has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue